Wobrain Medical Completes Strategic Funding Round to Accelerate Global Expansion in Neurovascular Medical Technology

On March 18, global neurovascular medical technology company WallabyPhenox announced the successful completion of a major equity financing round and debt restructuring. The round was jointly led by Yunfeng Capital, Hillhouse, Gaorong Ventures, Huajie Gaojing, Jiachen Capital, and Qianhai Ark Asset Management, with Enlight Medical participating as a follow-on investor. The proceeds will be used to optimize the company's capital structure and accelerate its long-term global growth strategy.

Founded in December 2015, WallabyPhenox focuses on delivering innovative, breakthrough, and clinically validated stroke treatment technologies and solutions. To date, the company operates five R&D centers and three manufacturing bases worldwide, employs over 700 staff, and holds more than 200 global patents.

WallabyPhenox has long been guided by its vision of "saving more stroke patients' lives," contributing continuously to global healthcare. Today, its comprehensive stroke solutions span three major areas — hemorrhagic stroke, ischemic stroke, and access — with sales networks covering more than 60 countries and regions including China, the US, major European economies, and Japan.

Strategic Merger Completed: Accelerating Global Expansion

The strong support from top-tier investment institutions and strategic partners for this round underscores capital markets' confidence in the continued expansion of WallabyPhenox's neurovascular platform. Following this milestone, Enlight Medical and WallabyPhenox have completed their strategic merger, forming a fully integrated cardiovascular medical company with enhanced global presence and influence.

Through this strategic merger, WallabyPhenox will effectively optimize its capital structure, increase operational flexibility, and provide solid support for key strategic initiatives, including the advancement of major clinical studies and the continued expansion of its global product portfolio.

Accelerating Clinical Innovation: Broadening Treatment Boundaries

WallabyPhenox is currently advancing its landmark US PIANO clinical trial, designed to further broaden the application of flow diversion therapy and expand coverage in neurovascular — one of the fastest-growing segments in the field. The company expects to complete first patient enrollment in the near future.

Meanwhile, the company has launched the TRUST registry study in Europe. As a global multi-center registry study, it aims to systematically evaluate the clinical outcomes of various neurovascular treatment approaches through real-world data. The launch of the TRUST registry demonstrates the company's long-term commitment to building robust clinical evidence across global markets.

Expanding the Frontier Technology Map: Building a Global R&D Ecosystem

With a pioneering spirit, the company has consistently explored cutting-edge fields: in 2012, it launched the world's first 64-wire flow diverter (p64), becoming the first company to validate its technology through a randomized controlled trial; through the COATING randomized controlled trial, it demonstrated the safety of simplifying antithrombotic regimens to single antiplatelet therapy (SAPT).

While continuing to consolidate its existing technological advantages, the company is now extending into frontier innovation areas, including an early-stage brain-computer interface (BCI) platform.

Looking Ahead: Reaching More Patients Globally

Dr. Ruilin Zhao, CEO of WallabyPhenox, stated: "This financing round, backed by multiple top-tier investment institutions, marks a pivotal moment in the company's development. While strengthening our financial foundation, we have also furthered our firm commitment to clinical excellence and global expansion. By combining proven neurovascular technologies with major clinical programs such as PIANO and TRUST, we are dedicated to benefiting more patients worldwide."